The FDA approved modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy that permit patients to take a pregnancy test outside of a medical setting during and after isotretinoin treatment ...

March 9, 2006 (San Francisco) — The largest and arguably most complex risk-management program ever undertaken by the US Food and Drug Administration is sparking a commensurate measure of controversy — ...

Test for pregnancy in medical setting before starting isotretinoin, then can be done at ho ...

More than a month after the launch of the new iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, the operation still isn't running smoothly for many dermatologists, pharmacists, and ...